Skyran News
July 2022
Skyran Biologics has received a phase II STTR grant “A novel PEDF peptide for diabetic retinopathy” from the National Institutes of Health to further its commercialization of PEDF peptide mimetics as a first in line therapy for diabetic retinopathy.
August 2022
Dr. Barnstable published the review article “Epigenetics and Degenerative Retinal Diseases: Prospects for New Therapeutic Approaches” in the Asia Pacific Journal of Ophthalmology.
January 2023
Dr. Barnstable has received a Stein Innovation Award from Research to Prevent Blindness for his work on the use of epigenetic modifiers as potential therapeutics in photoreceptor degenerations.
April 2023
Drs. Tombran-Tink and Barnstable are inventors on a patent submitted and assigned to the Penn State Research Foundation.
July 2023
Dr. Joyce Tombran-Tink has been appointed Chief Scientific Officer of Skyran Biologics
July 2023
Skyran Biologics has received a phase I STTR award “Epigenetic Modifiers to treat Photoreceptor Degenerations” from the National Institutes of Health with Dr. Joyce Tombran-Tink as principal investigator to develop epigenetic modifiers as therapeutics for retinitis pigmentosa and other photoreceptor degenerations.
December 2023
Drs. Tombran-Tink and Barnstable are co-authors of the study “A PEDF peptide mimetic effectively relieves dry eye in a diabetic murine model by restoring corneal nerve, barrier, and lacrimal gland function” published in the journal Ocular Surface.